Evaluation of the safety of four porcine circovirus type 2 tissue homogenate vaccines in a pig bioassay.
Ten four-week-old porcine circovirus type 2 (PCV-2) naive piglets were housed individually in a HEPA-filtered isolator and were randomly assigned to one of six treatment groups. Each of the two pigs in groups 1 to 4 received two intramuscular doses of 2 ml of one of four different autogenous tissue homogenate vaccines (THVs) 14 days apart, and the other two pigs received 2 ml of PCV-2 virus or sterile phosphate buffered saline. When the piglets were euthanased 14 days after the second dose, the injection sites were grossly and microscopically free of swelling, an inflammatory response or abscesses. The positive control pig, one of the two pigs in the THV-2 group and both pigs in the THV-3 group became viraemic. The PCV-2 DNA from the positive control pig and the pigs in the THV-3 group was identical to the PCV-2 DNA that they had been administered.